During the past decade, systemic treatment options for patients with advanced castration-resistant prostate cancer have expanded with the introduction and approval of the prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical lutetium Lu 177 vipivotide tetraxetan; the poly ADT ribose polymerase (PARP) inhibitors Olaparib, Rucaparib, Talazoparib, and Niraparib for homologous recombination-deficient (HRD) prostate cancer; and the checkpoint inhibitors nivolumab and pembrolizumab for mismatch repair-deficient (MSI-H) prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.